On May 1, 2014 Advaxis reported that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for ADXS-HPV, its lead immunotherapy drug candidate, for the treatment of Stage II-IV invasive cervical cancer (Press release Advaxis, MAY 1, 2014, View Source [SID:1234500482]).